Whether infection of cells by individual virions occurs randomly or if there is some form (s) of competition or cooperativity between individual virions remains largely unknown for most virus-cell ...

Researchers recently enhanced the titer of a cell line still in development to produce adenovirus viral vectors by 7.5-fold, and without the risk of also producing replication-competent adenoviruses ...

The review also calls for embedding diagnostics within the One Health framework, which integrates human, animal, and ...

Bluejay Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver diseases, today announced Week 48 treatment ...

Arbutus Biopharma Corporation ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today reported third quarter 2025 financial results and provided a ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech ...

IO360º today announced the 2026 sponsoring companies of the 12th annual Immuno-Oncology 360º Summit (IO360°) to date, who provide the capabilities the IO marketplace needs to advance the science.

Strong demand and clinical progress against high-incidence diseases, calls for gene therapy manufacturers to scale up ...

Background Globally, an estimated 296 million individuals live with chronic hepatitis B virus (HBV) infection, carrying ...

Virus entry is thought to involve binding a unique receptor for cell attachment and cytosolic entry. For SARS-CoV-2 underlying the COVID-19 pandemic, angiotensin- converting enzyme 2 (ACE2) is widely ...

All brelovitug dose regimens studied were well tolerated Results will be presented at The Liver Meeting® 2025 of AASLDAdditional preclinical data ...